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Background: Currently, it is now time for the development of the next generation of drug-eluting stents (DES) to guarantee more safe and efficient 
profile as compared to the first generation of DES. We compared the efficacy and safety of the new paclitaxel-eluting stents (CoroflexTM Please), 
compared with first-generation paclitaxel-eluting stents for coronary revascularization.
Methods: We performed a single-blind, multicenter, prospective randomized trial to compare the safety and efficacy of the CoroflexTM Please 
stent and TAXUS stent in patients with de novo coronary disease. The primary end point was an in-segment late luminal loss at 9-month follow-up 
angiography. Clinical events were also monitored for at least 12 months.
Results: A total of 319 patients were randomized 1:1 to received CoroflexTM Please stent (n=159) and paclitaxel-eluting stent (n=160). At 9 
month, the primary end-point of in-segment late loss was similar in patients receiving CoroflexTM Please stent and in those receiving Taxus stent 
(0.40±0.38 and 0.39±0.38, P=0.98). The rate of angiographic in-segment restenosis was also similar between 2 groups (22.2% and 18.8%, P=0.48). 
There were no significant between-group differences in the rate of death from cardiac causes, any myocardial infarction, or revascularization. The 
rate of definite or probable stent thrombosis was 0.6% in the CoroflexTM Please stent group and 1.3% in the Taxus stent group (P>0.99).
Conclusions: During 1 year of follow-up, the newer-generation paclitaxel-eluting CoroflexTM Please stent was found to be noninferior to early 
generation paclitaxel-eluting stent for coronary revascularization.
